Lion TCR is a clinical-stage T cell immunotherapy company specialized in the development and commercialisation of its proprietary technologic and engineered T cell products against viral-related cancers. As the world leader in HBV specific TCR redirected T cell therapy against HCC, the company has global exclusive licenses of the technologies from Singapore A*STAR. Lion TCR has developed various TCR-T technology platform including TCR discovery platform, autologous and allergenic TCR platform incorporating with gene editing technologies.
Looking for a particular Lion TCR employee's phone or email?
The Lion TCR annual revenue was $7 million in 2026.
Tina Tingting is the COO and CMO of Lion TCR.
12 people are employed at Lion TCR.
The NAICS codes for Lion TCR are [5417, 54, 541, 54171, 541714].
The SIC codes for Lion TCR are [873, 87].